Superworth

Viking Therapeutics VKTX

Drug Manufacturers - General, Healthcare
$26.83
−1.65%
Market cap
$3.4B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
n/a
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$0
Net margin
n/a
Free cash flow yield
n/m
not a meaningful number

Viking Therapeutics' trailing earnings are negative, so it has no PE. Revenue was $0 over the last twelve months.

Charts

Financials

Income statement for VKTX, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$0$0$0$0$0$0$0$0$0$0$0$0
R&D$20.5M+27%$24.1M+119%$23.8M+71%$22.8M+24%$31M+51%$41.4M+72%$60.2M+153%$90M+295%$153.5M+395%$150.2M+263%$115.8M+92%$166.8M+85%
SG&A$8.8M+114%$10M+5%$10.3M+5%$13.8M+55%$15.3M+74%$14.1M+41%$14.4M+40%$8.6M−38%$11.3M−26%$14M−1%$16.8M+17%$20.3M+136%
−$29.3M+44%−$34.1M+66%−$34.1M+43%−$36.6M+34%−$46.2M+58%−$55.5M+63%−$74.6M+119%−$98.6M+170%−$164.7M+256%−$164.1M+196%−$132.6M+78%−$187.1M+90%
Interest expensen/an/an/an/an/an/an/a$0n/an/an/a$88K
Net income−$24.6M+26%−$27.4M+40%−$22.3M+16%−$24.9M+11%−$35.4M+44%−$45.6M+67%−$65.6M+195%−$90.8M+264%−$157.7M+345%−$158.3M+247%−$128M+95%−$183.2M+102%
−$0.25−4%−$0.26+4%−$0.20+5%−$0.22−4%−$0.32+28%−$0.41+58%−$0.58+190%−$0.81+268%−$1.38+331%−$1.37+234%−$1.10+90%−$1.55+91%
99.9M+30%103.5M+32%110.4M+12%110.9M+11%111.3M+12%112.1M+8%112.1M+2%112.3M+1%114M+2%115.6M+3%116.3M+4%118M+5%

EPS, diluted: 12 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY14: share-days: the 12-month average less the 9-month, weighted by days. 11 periods, Q4 FY15 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Viking Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
VKTXViking Therapeutics$3.4Bn/mn/an/an/mn/a
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×2.1×+9%5.0%
KNSAKiniksa Pharmaceuticals International$7.1B93.6×87.6×8.4×+59%9.6%
Peer median$3.8B24.1×28.8×3.6×+20%17.2%

More on Viking Therapeutics

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .